Creative Biolabs recently has unprecedentedly achieved the precise identification of leucine and isoleucine by mass spectrometry, advancing breakthrough science on protein/antibody sequencing in research, diagnostic, and therapeutic industries. The discrimination of leucine and isoleucine has long been the key technical difficulties of de novo antibody sequencing. However, Creative Biolabs just took a massive leap forward into the new era of this field, with unchallenged ability to achieve 100% accuracy in antibody sequencing by precisely distinguishing between leucine and isoleucine, based on the proprietary Database Assisted Shotgun Sequencing (DASS) technology.
Our services consist of variable region, variable plus leader region, as well as full-length heavy- and light-chain antibody sequencing for all species, isotypes, and allotypes. Purified monoclonal antibodies in multivalent forms can be sequenced with 100% coverage of the desired regions as well as excellent accuracy. Numerous successful cases from Creative Biolabs have confirmed our qualification to provide antibody sequencing with 100% accuracy and satisfaction guarantee to meet our customers' needs.
Our world-leading DASS system provides reliable supporting proof for:
Based on our proprietary technology for de novo sequencing of antibodies and our expertise in protein mass spectrometry and informatics, our standard procedures for service include the following steps:Fig. 1 De Novo Antibody Sequencing Workflow.
The V and J and C gene segments of antibodies are available in public databases. However, during the maturation of an antibody, the B cell introduces hypermutations into the sequence to optimize the affinity. Our mapping algorithm is error tolerant and can match the "mutated" peptides to the corresponding germline, reliably.
Due to the high number of peptides, we get sequence information for EVERY peptide bond in the antibody. Typically, 20-70 different MS/MS spectra are generated for each amino acid (AA) position. Hence, even the hardest sequences of proline and arginine-rich peptides can be resolved. As the order of all amino acids is clear, there is no need for time-consuming techniques like Edman sequencing.
While the CDR3 of the light chain is mostly encoded by the germline sequences, the CDR3 of the heavy chain is usually not available in databases. It is encoded by the so-called D-segments, but these are modified by nucleases and terminal transferases. Typically, only 1-4 AA of a D-segment remains in the matured antibody. The rest of the D-segment is “artificial” and has to be sequenced de novo.
Our method generates many overlapping peptides during the fragmentation process, enabling us to sequence very long stretches of unknown amino acids. The high quality of MS/MS spectra in combination with intelligent data mining, allows us to read the CDR3 like a book. The technique is so powerful that we were able to sequence a 20 kDa protein, which had no homolog in the database.
In contrast to other MS-based methods, we can discriminate most isobaric amino acid combinations, which including but not limited to:Fig. 2 Sample Sequencing Results.
As we are aware that your projects have tight timelines, we validate the sequences to ensure that your antibody will be functional with the first attempt.
(1) The masses of the reduced light- and heavy-chain will be determined to validate the determined sequences. The light chain sequence must match within a +/- 1.2 Da range. For the heavy chain, +/- 1.8 Da is allowed. If the determined sequences do not match with the protein mass, you will not be charged. (Please note that this deviation is less than the weight of two protons).
(2) Each mutation in the antibody will be validated by at least two meaningful spectra. This ensures that your sequence does not contain isobaric exchanges. Do not rely on peptide maps alone. [Isobaric exchanges are exchanges of identical mass like GG=N, YM=FM (Ox). The peptide maps used by some competitors are often not sensitive to this kind of error].
If we do not reach at least 5× coverage for the complete V(D)J-region, you will not be charged. You can also book our 10× service. We will not stop to sequence unless we have 10× coverage for V(D)J.
The one and only: Discrimination of leucine & isoleucine.
Fast: Sequencing can be accomplished within 10 working days. Additional 2~3 weeks would be needed if the discrimination of leucine & isoleucine is required.
Sensitive: Full coverage can be obtained from 50-100 μg of protein.
Robust: We guarantee 100% coverage for the VJ and VDJ region.
High-throughput: Our DASS method is high-throughput compatible. We would be pleased to plan your project with 100, 200, 500 or more antibodies.
Professional: Highly experienced Ph.D. scientists in charge of every project with a specialized team for quality control in every step of the process; expert R&D team dedicated to the optimization of protocols to deliver data with enhanced quality.
Integrity: Custom services including but not limited to antibody designing, cloning, de novo sequencing and analyzing, as well as in vitro optimization to fulfill your needs.
If you are interested in our DASS technology, please feel free to inquire us for more details.
All listed customized services & products are for research use only, not intended for pharmaceutical, diagnostic, therapeutic or any in vivo human use.